Cyclin D1 Overexpression and p53 Mutation Status in Epithelial Ovarian Cancer

Abstract

Objective: To examine the cyclin D1 mRNA expression level in ovarian tumor samples as compared with normal ovaries and to determine the relationship between cyclin D1 overexpression and p53 mutation status in ovarian tumors.

Methods: mRNA was isolated and cDNA was prepared from 27 epithelial ovarian turmors (3 tumors of low malignant potential (LMP) and 24 cancers) and 6 normal ovaries. The cyclin D1 sequences were amplified by using a thermal cycler in parallel with the β-tubulin gene as internal control. The cyclin D1 mRNA expression level relative to β-tubulin was determined by ³²P phosphoimager analysis. To confirm the overexpression of the cyclin D1 protein ovarian tumor cells, immunostaining was performed. The p53 gene mutations status was examined by direct cDNA sequencing.

Results: mRNA levels of cyclin D1 were significantly higher in 21 (78%) of the 27 ovarian tumors than in normal ovaries. Cyclin D1 overexpression was detected in ovarian LMP tumors as well as in ovarian cancer cases. Positive immunostaining of cyclin D1 protein was observed in 10 of 18 (56%) ovarian tumors examined. p53 mutations were found in 11 (61%) of 18 ovarian tumors. Of 11 ovarian tumor cases with p53 mutations, 5 showed overexpression of cyclin D1. All 7 ovarian tumor cases without p53 mutations showed significant cyclin D1 mRNA overexpression.

Conclusion: Cyclin D1 overexpression seems to be an early genetic event in ovarian tumor development. Although p53 may be one of the proteins whose function regulates the expression of G1 cyclins, ovarian tumors with no p53 mutation consistently showed cyclin D1 overexpression. Cyclin D1 overexpression may play an important role in the tumorigenesis of epithelial ovarian tumors.

Keywords

Cyclin D1 epithelial ovarian cancer p53 mutation

Get full access to this article

View all access options for this article.

References

1. Grana X , Reddy EP . Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase (CK1s). Oncogene 1995;11:211-219.

2. Inba T , Matsushime H , Valentine M , Roussel MF , Sherr CJ , Look AT . Genonic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics 1992;13:565-574.

3. Xiong Y , Menninger J , Beach D , Ward DC . Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins. Genomics 1992;13:575-584.

4. Hunter T , Pines J . Cyclins nd cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.

5. Arnold A , Kim HG , Gaz RD , et al, Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 1989;83:2034-2040.

6. Rosenberg CL , Kim HG , Shows TB , Kronenberg HM , Arnold A . Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene 1991;6:449-445.

7. Rosenberg CL , Wang E , Petty EM , et al. PRAD1, a candidate BCL1 oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991;88:9638-9642.

8. Lammie GA , Fantl V , Smith R , et al. D11S287, a putative oncogene an chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991;6:439-444.

9. Schuuring E , Verhoeven E , Mooi WJ , Michalides RJAM , Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992;7:355-361.

10.

10. Jiang W , Zhang YJ , Kahn SM , et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993;90:9026-9030.

11.

11. Motokura T , Arnold A . Cyclins and oncogenesis. Biochim Biophys Acta 1993;1153:63-78.

12.

12. Worsley SD , Ponder BAJ , Davies BR . Overexpression of cyclin D1 in epithelial overian cancers. Gynecol Oncol 1997;64:189-195.

13.

13. Kypryjanczyk J , Thor AD , Beauchamp R , et al. p53 gene mutation and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90: 4961-4965.

14.

14. Milner BJ , Allan LA , Eccles DM . et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993;53:2128-2132.

15.

15. Kohler MF Marks JR , Wiseman RW et al. Spectrum of mutation and frequently of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-1519.

16.

16. Niwa K , Itoh M , Murase T , et al. Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 1994;70:1191-1197.

17.

17. McManus DT , Yap EPH , Maxwell P , Russel SEH , Toner PG , McGee JO'D . p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 1994;174:159-168.

18.

18. Teneriello MG , Ebina M , Linnoila RI , et al. p53 and K-ras genemutation in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-3108.

19.

19. Xiong Y , Hannon GJ , Zhang H , Casso D , Kobayashi R , Beach D . p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.

20.

20. El-Deiry WS , Tokino T , Velculescu VE , et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.

21.

21. Harper JW , Adami GR Wei N , Keyomarsi K , Elledge SJ . The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.

22.

22. Noda A , Ning Y , Venable SF , Pereia-Smith OM , Smith JR . Cloning of senescent cell-derived inhibiators of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-98.

23.

23. Shigemasa K , Hu C , West CM et al. p21: A monitor of p53 dysfunction in ovarian neoplasia. Int J Gynecol Cancer 1997;7:296-303.

24.

24. Shigemasa K , Hu C , West CM , et al. p16 overexpression: A pontential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Invest 1997;4:95-102.

25.

25. Noonan KE , Beck C , Holzmayer TA , et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:7160-7164.

26.

26. Xiong Y , Connolly T , Futcher B , Beach D , Human D-type cyclin. Cell 1991;65:691-699.

27.

27. Hall JL , Dudley L , Dobner PR , Lewis SA , Cowan NJ . Identification of two human β-tubulin isotopes. Mol Cell Biol 1983;3:854-862.

28.

28. Lamb P , Crawford L . Characterization of the human p53 gene. Mol Cell Biol 1986;6:1379-1385.

29.

29. Hinds PW , Dowdy SF , Eaton EN , Arnold A , Weinberg RA . Function of a human cyclinn gene as an oncogene. Proc Natl Acad Sci USA 1994;91:709-713.

30.

30. Jiang W , Kahn SM , Zhou P , et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993;8:3447-3457.

31.

31. Lovec H , Sewing A , Lucibello FC , Muller R , Moroy T . Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: Link between cell cycle control and malignant transformation. Oncogene 1994;9:323-326.

32.

32. Wang TC , Cardiff RD , Zukerberg L , Lees E , Arnold A , Schmidt EV . Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-671.

33.

33. Bito T , Ueda M , Ahmed NU , Nagano T , Ichihashi M . Cyclin D and retinoblastoma gene product expression in actinic keratosis and cutaneous squamous cell carcinoma in relation to p53 expression. J Cutan Pathol 1995;22:427-434.

34.

34. Michalides RJAM , van Veelen NMJ , Kristel PMP , et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1997;123:497-502.

35.

35. Uchimaru K , Endo K , Fujimura H , Zukerberg L , Arnold A , Motokura T . Oncogenic collaboration of the cyclin D1 (PRAD1, bcl-1) gene with a mutated p53 and an activated ras oncogene in neoplastic transformation. Jpn J Cancer Res 1996;87:459-465.